论文部分内容阅读
Sorafenib is an effective anti-angiogenic treatment forhepatocellular carcinoma (HCC). The assessment oftumor progression in patients treated with sorafenibis crucial to help identify potentially-resistant patients,avoiding unnecessary toxicities. Traditi